Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
A team from ORNL, Stanford University and Purdue University developed and demonstrated a novel, fully functional quantum local area network, or QLAN, to enable real-time adjustments to information shared with geographically isolated systems at ORNL
A team led by the ORNL has found a rare quantum material in which electrons move in coordinated ways, essentially “dancing.”
Sergei Kalinin, a scientist and inventor at the Department of Energy’s Oak Ridge National Laboratory, has been elected a fellow of the Microscopy Society of America professional society.
A joint research team from Google Inc., NASA Ames Research Center, and the Department of Energy’s Oak Ridge National Laboratory has demonstrated that a quantum computer can outperform a classical computer
ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.
A team led by scientists at the Department of Energy’s Oak Ridge National Laboratory explored how atomically thin two-dimensional (2D) crystals can grow over 3D objects and how the curvature of those objects can stretch and strain the
OAK RIDGE, Tenn., May 7, 2019—The U.S. Department of Energy today announced a contract with Cray Inc. to build the Frontier supercomputer at Oak Ridge National Laboratory, which is anticipated to debut in 2021 as the world’s most powerful computer with a performance of greater than 1.5 exaflops.
OAK RIDGE, Tenn., May 7, 2019—Energy Secretary Rick Perry, Congressman Chuck Fleischmann and lab officials today broke ground on a multipurpose research facility that will provide state-of-the-art laboratory space
OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.